

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: <b>Zasloff et al.</b>	)	Confirmation No. <b>7684</b>
	)	
Application No. <b>10/824,661</b>	)	Examiner: <b>Sabiha N. Qazi, Ph.D.</b>
	)	
Filing Date: <b>April 15, 2004</b>	)	Group Art Unit: <b>1616</b>
	)	
For: <b>Treatment of Neovascularization Disorders</b>	)	
<b>With Squalamine (amended)</b>	)	Date: November 19, 2007

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97(c)**

Pursuant to 37 C.F.R. 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the document listed on the attached PTO-1449. This Information Disclosure Statement is being filed to the best of the undersigned's knowledge before the mailing date of a Final Office Action or a Notice of Allowance for the above-referenced application. Under the provisions of 37 C.F.R. 1.97(c), the Commissioner is hereby authorized to charge the fee of \$180.00 as specified by 1.17(p) to Deposit Account 50-0310.

The above-identified patent application is a continuation application under 37 C.F.R. 1.53(b) of Application No. 09/985,417 (filed November 2, 2001), now U.S. Patent 6,962,909 (issued November 8, 2005), which is a continuation application of Application No. 09/198,486 (filed November 24, 1998), which is a continuation application of Application No. 08/487,443 (filed June 7, 1995), now U.S. Patent 5,847,172 (issued December 8, 1998). Because copies of all of the non-U.S. patent documents listed on the attached PTO 1449 forms were provided to the Examiner in the parent application, no copies are being submitted herein.

Applicants respectfully request that the Examiner initial and return the PTO-1449 forms, indicating that the information has been considered and made of record herein.


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the listed documents are material or constitute "prior art." If it should be determined that the listed documents constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of each of the documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should the documents be applied against the claims of the present application.

**Except** for issue fees payable under 37 C.F.R. 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **constructive petition for extension of time** in accordance with 37 C.F.R. 1.136(a)(3).

Dated: **November 19, 2007**  
Morgan, Lewis & Bockius LLP  
Customer No. **09629**  
1111 Pennsylvania Avenue  
Washington, D.C. 20004  
202-739-3000

Respectfully submitted,  
**Morgan, Lewis & Bockius LLP**

  
\_\_\_\_\_  
Gregory T. Lowen  
Registration No. 46,882